PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Alicia K. Morgans, MD, MPH - Creating a Roadmap for Modern Prostate Cancer Treatment: How to Use the Most Recent Evidence on Novel Therapeutic Strategies and Shared Decision-Making to Personalize Patient Care
Go online to PeerView.com/XGS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Two experts highlight how a prostate cancer care team can use the latest clinical evidence, treatment guidelines, and consensus recommendations to improve outcomes for patients with prostate cancer and will give practical insights on applying next-generation anti-androgen agents, PARP inhibitors, and chemotherapy to the prostate cancer treatment landscape. By providing a “roadmap” to the multiple pathways of prostate cancer management, this program serves as a resource for professionals interested in the present and future applications of new science in patient care. Upon completion of this activity, participants should be better able to: Review current guideline recommendations related to germline and somatic tumor testing in patients with prostate cancer; Select patients with advanced prostate cancer who are likely to benefit from novel systemic therapies and combination strategies based on recent clinical evidence, regulatory updates, genetic/molecular status, and current practice guidelines; and Implement personalized treatment plans for patients with advanced prostate cancer that incorporate new agents and combinations, expert recommendations, shared decision- making, and multidisciplinary team-based care.